S Krähenbühl
Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
Neumair P, Cerny T, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Dutly A, Warschkow R, Joos L, Jörger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. Lung Cancer 2016; 100:38-44.
28.07.2016Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study
28.07.2016Lung Cancer 2016; 100:38-44
Neumair P, Cerny Thomas, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Dutly A, Warschkow Rene, Joos L, Jörger Markus
Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
Neumair P, Krähenbühl S, Baty F, Brutsche M, Früh M, Hitz F, Ess S, Warschkow R, Joos L, Jörger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study - Abstrakt 169P.
15.04.2016Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study
15.04.2016European Lung Cancer Conference
Neumair P, Krähenbühl S, Baty Florent, Brutsche Martin, Früh Martin, Hitz Felicitas, Ess S, Warschkow Rene, Joos L, Jörger Markus
Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach.
Halter J, Schüpbach W, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, Lehmann T, Mandel H, Martinez R, Mattle H, Orchard K, Savage D, Sue C, Valcarcel D, Gratwohl A, Hirano M. Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach. Bone Marrow Transplant 2010; 46:330-337.
03.05.2010Allogeneic hematopoietic SCT as treatment option for patients with mitochondrial neurogastrointestinal encephalomyopathy (MNGIE): a consensus conference proposal for a standardized approach.
03.05.2010Bone Marrow Transplant 2010; 46:330-337
Halter J, Schüpbach Wmm, Casali C, Elhasid R, Fay K, Hammans S, Illa I, Kappeler L, Krähenbühl S, Lehmann Thomas, Mandel H, Martinez Raquel, Mattle Heinrich P, Orchard K, Savage David B, Sue C M, Valcarcel D, Gratwohl A, Hirano M
[Seizure and non-cardiogenic pulmonary edema after intoxication]
Sawatzki M, Kummer O, Krähenbühl S, Siegemund M. [Seizure and non-cardiogenic pulmonary edema after intoxication]. Internist (Berl) 2010; 51:528-32.
01.04.2010[Seizure and non-cardiogenic pulmonary edema after intoxication]
01.04.2010Internist (Berl) 2010; 51:528-32
Sawatzki Mikael, Kummer O, Krähenbühl S, Siegemund M
Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
Jörger M, Huitema A, Krähenbühl S, Schellens J, Cerny T, Reni M, Zucca E, Cavalli F, Ferreri A. Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial. Br J Cancer 2010; 102:673-7.
02.02.2010Methotrexate area under the curve is an important outcome predictor in patients with primary CNS lymphoma: A pharmacokinetic-pharmacodynamic analysis from the IELSG no. 20 trial
02.02.2010Br J Cancer 2010; 102:673-7
Jörger Markus, Huitema A D R, Krähenbühl S, Schellens J H M, Cerny Thomas, Reni M, Zucca E, Cavalli F, Ferreri A J M